KURA Stock Analysis: Buy, Sell, or Hold?
KURA - Kura Oncology, Inc.
$11.10
0.32 (2.97%)
▲
5d:
+7.14%
30d:
+23.75%
90d:
+33.09%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Smart Money Accumulation
None View Scanner →
Strength: 6.6/10
Get Alerted When KURA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: KURA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: KURA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: KURA is currently trading at $11.10, which is considered extended relative to its 30-day fair value range of $8.93 to $10.62.
Technical Outlook: Technically, KURA is in a strong uptrend. The price is approaching resistance at $11.20. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KURA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $31.17 (+180.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KURA is in a strong uptrend. The price is approaching resistance at $11.20. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KURA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $31.17 (+180.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.93 -
$10.62
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 180.8% below Wall St target ($31.17)
Trading Range Analysis
30-Day Trading Range
$8.93 -
$10.62
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$9.55
Resistance Level
$11.20
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.27
Wall Street Target
$31.17
(+180.8%)
Revenue Growth (YoY)
29.5%
Share & Embed Analysis
Last updated: July 02, 2026 10:42 PM ET
Data refreshes hourly during market hours. Next update: 11:42 PM
Data refreshes hourly during market hours. Next update: 11:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KURA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Francis Burrows
SELL
1311 shares
2026-01-27
Kathleen Ford
SELL
1813 shares
2026-01-27
Mollie Leoni
SELL
8180 shares
2026-01-27
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 56 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 62 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
